- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about ABCL
Recent news which mentions ABCL
3 Biotech Stocks Under $10 to Add to Your Buy List
April 26, 2022
From InvestorPlace
AbCellera Biologics Inc. (ABCL) Q4 2021 Earnings Call Transcript
February 25, 2022
Tickers
ABCL
From Motley Fool
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
February 24, 2022
From Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
From Benzinga
From Benzinga
Is It Time to Buy the Nasdaq's 11 Worst-Performing Stocks of 2021?
December 08, 2021
From Motley Fool
Lilly's COVID-19 Antibody Cocktail Scores FDA Emergency Use For Kids, Including Newborns
December 06, 2021
From Benzinga
These Biotech Companies Are Attempting to Use Improved Antibody Technology in the Fight To Eradicate COVID-19
November 29, 2021
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
November 19, 2021
From Benzinga
AbCellera Biologics Inc. (ABCL) Q3 2021 Earnings Call Transcript
November 10, 2021
Tickers
ABCL
From Motley Fool
How Bad Are AbCellera Biologics's Earnings? | Return On Capital Employed
November 09, 2021
Tickers
ABCL
From Benzinga
Why AbCellera Biologics Stock Sank 21.6% in October
November 04, 2021
From Motley Fool
Why AbCellera Biologics Stock Jumped 19.4% Last Month
October 07, 2021
From Motley Fool
AbCellera, Everest Medicines Team Up To Develop 10 Therapeutic Antibodies
September 23, 2021
Tickers
ABCL
From Benzinga
The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
September 23, 2021
From Benzinga
Cramer's Advice On Ulta Beauty, Laredo Petroleum And More
September 23, 2021
From Benzinga
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
September 17, 2021
From Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
September 17, 2021
From InvestorPlace
15 Stocks Moving in Friday's Pre-Market Session
September 17, 2021
From Benzinga
AbCellera Stock Is Moving Higher After Expanded Use Nod For Lilly-Partnered COVID-19 Antibody
September 17, 2021
From Benzinga
Why AbCellera Biologics Stock Jumped 7% on Wednesday
September 15, 2021
From Motley Fool
AbCellera Shares Are Moving Higher On Licensing Pact With Moderna
September 15, 2021
From Benzinga
Here's Why AbCellera Biologics Stock Gained 10.6% Last Month
September 04, 2021
From Motley Fool
78 Biggest Movers From Friday
August 16, 2021
From Benzinga
Why AbCellera Biologics Stock Was Up More Than 17% on Friday
August 13, 2021
From Motley Fool
53 Stocks Moving In Friday's Mid-Day Session
August 13, 2021
From Benzinga
AbCellera Biologics Inc. (ABCL) Q2 2021 Earnings Call Transcript
August 13, 2021
Tickers
ABCL
From Motley Fool
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.